- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HEMOGENYX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 03.04. | Hemogenyx Pharmaceuticals PLC Announces FDA Annual Report | 128 | ACCESS Newswire | Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML LONDON, UK / ACCESS Newswire / April 3, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce... ► Artikel lesen | |
| 03.04. | Hemogenyx Pharma Plc - FDA Annual Report | 2 | RNS | ||
| 31.03. | Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights | 123 | ACCESS Newswire | LONDON, GB / ACCESS Newswire / March 31, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total... ► Artikel lesen | |
| 31.03. | Hemogenyx Pharma Plc - Total Voting Rights | 1 | RNS | ||
| 24.03. | Hemogenyx Pharmaceuticals PLC Announces First Patient Safety | 170 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS... ► Artikel lesen | |
| 24.03. | Hemogenyx Pharma Plc - First Patient Safety | 1 | RNS | ||
| 17.03. | Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials | 185 | ACCESS Newswire | Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second... ► Artikel lesen | |
| 17.03. | Hemogenyx Pharma Plc - Recruitment of Second Patient for Clinical Trials | - | RNS | ||
| 13.03. | Hemogenyx Pharma Plc - Conversion of convertible loan notes | 1 | RNS | ||
| 11.03. | Hemogenyx Pharmaceuticals PLC Announces Institutional Investment | 120 | ACCESS Newswire | Institutional backing of £709,200 for continuing Phase 1 Clinical Trials LONDON, UNITED KINGDOM / ACCESS Newswire / March 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) ("Hemogenyx Pharmaceuticals"... ► Artikel lesen | |
| 11.03. | Hemogenyx Pharma Plc - Institutional investment | 1 | RNS | ||
| 24.02. | Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1 | 167 | ACCESS Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS... ► Artikel lesen | |
| 24.02. | Hemogenyx Pharma Plc - First-in-Human Treatment with HG-CT-1 | - | RNS | ||
| 19.02. | Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes | 343 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / February 19, 2025 / NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA... ► Artikel lesen | |
| 19.02. | Hemogenyx Pharmaceuticals sammelt 285.000£ durch Wandelanleihen ein | 3 | Investing.com Deutsch | ||
| 19.02. | Hemogenyx Pharmaceuticals raises £285,000 via convertible notes | 3 | Investing.com | ||
| 19.02. | Hemogenyx Pharma Plc - Issue of convertible loan notes | 1 | RNS | ||
| 31.01. | Hemogenyx Pharma Plc - Total Voting Rights | 1 | RNS | ||
| 08.01. | Hemogenyx Pharmaceuticals PLC Announces Placing to raise £340,000 | 214 | ACCESS Newswire | LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares")... ► Artikel lesen | |
| 08.01. | Hemogenyx Pharma Plc - Placing to raise £340,000 | 1 | RNS |
Seite:
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 0,112 | +2,29 % | InnoCan Pharma Aktie: Leichte Erholung nach Talfahrt | InnoCan Pharma verzeichnet leichten Aufwärtstrend, bleibt aber mit deutlichen Verlusten konfrontiert. Wie nachhaltig ist die aktuelle Erholung? Die InnoCan Pharma Aktie hat am Dienstag eine kleine Gegenbewegung... ► Artikel lesen | |
| WPD PHARMACEUTICALS | 0,050 | 0,00 % | CSE Bulletin: Consolidation - WPD Pharmaceuticals Inc. (WBIO) | le 23 décembre/December 2024
WPD Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every twenty-five... ► Artikel lesen | |
| MYDECINE INNOVATIONS GROUP | 0,002 | 0,00 % | Aquis Stock Exchange: Withdrawal from Trading - Mydecine Innovations Group Inc. | Aquis Stock Exchange
Aquis Stock Exchange: Withdrawal from Trading 02-Apr-2025 / 07:00 GMT/BST
The issuer is solely responsible for the content of this... ► Artikel lesen | |
| METSERA | 19,510 | 0,00 % | Why did Lilly data for oral GLP-1 boost Structure and Metsera? | ||
| HARROW | 23,240 | -3,13 % | Harrow Health Aktie: Ein dunkler Schatten fällt! | Das Pharmaunternehmen verbucht starke Quartalszahlen mit 66,83 Millionen Dollar Umsatz, während die Aktie dennoch einen Abwärtstrend von 5,75% fortsetzt. Der Aktienkurs von Harrow Health ist am Freitag... ► Artikel lesen | |
| UNIVERSE PHARMACEUTICALS | 4,250 | 0,00 % | Universe Pharmaceuticals Plans To Effect Share Consolidation | BEIJING (dpa-AFX) - Universe Pharmaceuticals (UPC) said it plans to effect a share consolidation of 40 ordinary shares with par value of $0.28125 per share each in the companys issued
and... ► Artikel lesen | |
| ZHENGYE BIOTECHNOLOGY | 7,920 | 0,00 % | Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering | Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 4,110 | +1,73 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 14,260 | -0,56 % | Eton Pharmaceuticals Out-Licenses International Rights to Increlex | DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 1,290 | 0,00 % | Sunshine Biopharma Inc.: Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 2,585 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Anaphylm (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | 1,010 | 0,00 % | China SXT Pharmaceuticals Stock Surges 90% | ||
| SHINECO | 0,509 | 0,00 % | Shineco, Inc.: Shineco Announces Acquisition of Medical Device Company | The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,015 | 0,00 % | Milestone Pharmaceuticals Inc.: FDA Issues Complete Response Letter for Etripamil for PSVT | CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025... ► Artikel lesen | |
| OMNIAB | 1,825 | +1,96 % | OmniAb expands board with two new directors |
HEMOGENYX PHARMACEUTICALS PLC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +1,59 % bei einem Aktienkurs von 1,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOGENYX PHARMACEUTICALS PLC finden Sie auf Wallstreet Online.
